Boundless Bio (BOLD) Profit After Tax (2023 - 2026)

Boundless Bio (BOLD) has reported Profit After Tax for 4 consecutive years, with -$13.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 13.69% year-over-year to -$13.6 million; the TTM figure through Mar 2026 stood at -$56.0 million (up 14.64% YoY), while the FY2025 annual figure was -$58.2 million, up 10.85% from the prior year.
• Profit After Tax eased to -$13.6 million in Q1 2026 per BOLD's latest filing, from -$12.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$11.7 million in Q1 2023 and bottomed at -$17.0 million in Q2 2024.
• Historically, Profit After Tax has averaged -$14.3 million across 4 years, with a median of -$13.9 million in 2025.
• Annual changes were most pronounced in 2024 — Profit After Tax tumbled 36.7% — and 2025, when it gained 21.71%.
• Boundless Bio's Profit After Tax stood at -$12.1 million in 2023, then slumped by 34.77% to -$16.4 million in 2024, then increased by 21.71% to -$12.8 million in 2025, then dropped by 6.13% to -$13.6 million in 2026.
• Business Quant data shows BOLD's Profit After Tax at -$13.6 million in Q1 2026, -$12.8 million in Q4 2025, and -$13.9 million in Q3 2025.